Last 12 months
Inside the activity.
0 purchase rows · 27 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 10 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 30, 2017 Filed Jun 1, 2017 21:25 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 3,650 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-015008 · doc4.xml · derivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,443 Underlying: Common Shares · 3,650 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:25 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 3,650 | $15.02 | $54,828.84 |
DisclosureSEC source: 0000899243-17-015008 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.04, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 30, 2017 Filed Jun 1, 2017 21:25 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 3,650 | $1.81 | $6,606.50 |
DisclosureSEC source: 0000899243-17-015008 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,218,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:43 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 25,923 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · derivative · entry 6 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,093 Underlying: Common Shares · 25,923 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:43 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 25,923 | $16.03 | $415,576.80 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.59 to $16.56, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2017 Filed May 18, 2017 22:43 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 25,923 | $1.81 | $46,920.63 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,240,928 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 16, 2017 Filed May 18, 2017 22:43 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 24,077 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · derivative · entry 5 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,016 Underlying: Common Shares · 24,077 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 16, 2017 Filed May 18, 2017 22:43 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 24,077 | $16.50 | $397,282.54 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.29 to $17.10, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 16, 2017 Filed May 18, 2017 22:43 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 24,077 | $1.81 | $43,579.37 |
DisclosureSEC source: 0000899243-17-013806 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,239,082 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 05, 2017 Filed May 9, 2017 21:28 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 616 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-012492 · doc4.xml · derivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,093 Underlying: Common Shares · 616 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 05, 2017 Filed May 9, 2017 21:28 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 616 | $16.92 | $10,425.68 |
DisclosureSEC source: 0000899243-17-012492 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.76 to $17.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 05, 2017 Filed May 9, 2017 21:28 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 616 | $1.81 | $1,114.96 |
DisclosureSEC source: 0000899243-17-012492 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,621 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 04, 2017 Filed May 4, 2017 21:44 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 13,191 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · derivative · entry 10 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,709 Underlying: Common Shares · 13,191 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 04, 2017 Filed May 4, 2017 21:44 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 13,191 | $16.37 | $215,960.41 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 7 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.90 to $16.78, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 04, 2017 Filed May 4, 2017 21:44 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 13,191 | $1.81 | $23,875.71 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 6 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,229,196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2017 Filed May 4, 2017 21:44 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 20,269 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · derivative · entry 9 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,900 Underlying: Common Shares · 20,269 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 03, 2017 Filed May 4, 2017 21:44 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 1,022 | $16.64 | $17,002.61 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 5 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.51 to $16.84, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2017 Filed May 4, 2017 21:44 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 19,247 | $16.05 | $308,983.64 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,216,027 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.51 to $16.45, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 03, 2017 Filed May 4, 2017 21:44 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 20,269 | $1.81 | $36,686.89 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,235,274 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2017 Filed May 5, 2017 22:39 UTC |
Kulkarni SamarthPlease See Remarks
|
GrantStock Options (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $16.21 | $0.00 |
DisclosureSEC source: 0000899243-17-012013 · doc4.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Please See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2027-05-03 F1 · derivative.exercise_date: This option was granted on May 3, 2017 with respect to 100,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning May 31, 2017. Read SEC document |
| May 02, 2017 Filed May 4, 2017 21:44 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · derivative · entry 8 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,169 Underlying: Common Shares · 50,000 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| May 02, 2017 Filed May 4, 2017 21:44 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 15,924 | $16.53 | $263,236.46 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.30 to $17.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 02, 2017 Filed May 4, 2017 21:44 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 15,924 | $1.81 | $28,822.44 |
DisclosureSEC source: 0000899243-17-011883 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,230,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 01, 2017 Filed May 3, 2017 21:17 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 1,852 | $16.61 | $30,753.39 |
DisclosureSEC source: 0000899243-17-011672 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,204 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.55 to $16.99, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 28, 2017 Filed Apr 28, 2017 22:12 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 4,912 | $16.62 | $81,637.93 |
DisclosureSEC source: 0000899243-17-011230 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,056 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.55 to $16.86, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 22:13 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 2,206 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · derivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,558 Underlying: Common Shares · 3,500 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 22:13 UTC |
Kulkarni SamarthChief Business Officer
|
SaleCommon Shares | 2,206 | $16.78 | $37,022.86 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.57 to $16.99, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 22:13 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionCommon Shares | 2,206 | $1.81 | $3,992.86 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 27, 2017 Filed Apr 28, 2017 22:12 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 13,527 | $16.84 | $227,798.74 |
DisclosureSEC source: 0000899243-17-011230 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,968 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.57 to $17.02, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 22:13 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 3,275 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · derivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 296,764 Underlying: Common Shares · 3,275 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 22:13 UTC |
Kulkarni SamarthChief Business Officer
|
SaleCommon Shares | 3,275 | $16.74 | $54,816.30 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.57 to $17.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 22:13 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionCommon Shares | 3,275 | $1.81 | $5,927.75 |
DisclosureSEC source: 0000899243-17-011231 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 26, 2017 Filed Apr 28, 2017 22:12 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 3,200 | $16.76 | $53,640.64 |
DisclosureSEC source: 0000899243-17-011230 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $17.00, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 25, 2017 Filed Apr 25, 2017 23:37 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 4,800 | $16.87 | $80,989.92 |
DisclosureSEC source: 0000899243-17-010883 · doc4.xml · nonDerivative · entry 3 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,695 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.65 to $17.10, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 25, 2017 Filed Apr 25, 2017 23:36 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 5,115 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · derivative · entry 9 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,039 Underlying: Common Shares · 5,115 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 25, 2017 Filed Apr 25, 2017 23:36 UTC |
Kulkarni SamarthChief Business Officer
|
SaleCommon Shares | 5,115 | $16.87 | $86,290.05 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 6 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.70 to $17.10, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 25, 2017 Filed Apr 25, 2017 23:36 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionCommon Shares | 5,115 | $1.81 | $9,258.15 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 139,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:37 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 3,522 | $16.44 | $57,897.10 |
DisclosureSEC source: 0000899243-17-010883 · doc4.xml · nonDerivative · entry 2 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,495 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.26 to $16.91, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:36 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 3,500 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · derivative · entry 8 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,154 Underlying: Common Shares · 3,500 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:36 UTC |
Kulkarni SamarthChief Business Officer
|
SaleCommon Shares | 3,500 | $16.46 | $57,619.45 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.21 to $16.98, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 24, 2017 Filed Apr 25, 2017 23:36 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionCommon Shares | 3,500 | $1.81 | $6,335.00 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,547 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 23:37 UTC |
Dylan-Hyde TylerChief Legal Officer
|
SaleCommon Shares | 3,010 | $17.02 | $51,222.37 |
DisclosureSEC source: 0000899243-17-010883 · doc4.xml · nonDerivative · entry 1 Dylan-Hyde Tyler · CIK 0001682027 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,017 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.85 to $17.21, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 23:36 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · derivative · entry 7 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,654 Underlying: Common Shares · 3,000 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 23:36 UTC |
Kulkarni SamarthChief Business Officer
|
SaleCommon Shares | 3,000 | $17.01 | $51,032.70 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.86 to $17.24, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 21, 2017 Filed Apr 25, 2017 23:36 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionCommon Shares | 3,000 | $1.81 | $5,430.00 |
DisclosureSEC source: 0000899243-17-010882 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,047 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:35 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 2,294 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · derivative · entry 7 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,093 Underlying: Common Shares · 2,294 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 share immediately vested on the grant date and the remaining 173,143 shares vest in 31 equal monthly installments thereafter. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:35 UTC |
Novak RodgerDirector · Chief Executive Officer
|
SaleCommon Shares | 2,294 | $17.37 | $39,851.83 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · nonDerivative · entry 5 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,215,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $17.53, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:35 UTC |
Novak RodgerDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 2,294 | $1.81 | $4,152.14 |
DisclosureSEC source: 0000899243-17-010733 · doc4.xml · nonDerivative · entry 4 Novak Rodger · CIK 0001682017 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,217,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:32 UTC |
Kulkarni SamarthChief Business Officer
|
Exercise / conversionStock Options (Right to Buy) · Derivative | 2,800 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · derivative · entry 7 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,654 Underlying: Common Shares · 2,800 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| April 20, 2017 Filed Apr 21, 2017 20:32 UTC |
Kulkarni SamarthChief Business Officer
|
SaleCommon Shares | 2,800 | $17.36 | $48,621.16 |
DisclosureSEC source: 0000899243-17-010731 · doc4.xml · nonDerivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,047 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.17 to $17.60, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.